keyword
MENU ▼
Read by QxMD icon Read
search

Zoledronic acid

keyword
https://www.readbyqxmd.com/read/28740535/acute-severe-diarrhoea-and-hyponatremia-after-zoledronic-acid-infusion-an-acute-phase-reaction
#1
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Ambrish Mithal
Zoledronic acid (ZA), an intravenous aminobisphosphonate, is prescribed widely for postmenopausal osteoporosis. It is a relatively safe drug but may cause adverse effects including acute phase reaction. Oral non-aminobisphosphonates are known to cause diarrhoea that is usually mild and self-limited. Intravenous amino-bisphosphonates are not known to cause diarrhoea. We describe a case of acute watery diarrhoea complicated by severe hyponatremia and hypotension following ZA infusion. The patient needed intensive care for four days...
January 2017: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/28740523/the-effects-of-zoledronic-acid-on-ecg-a-prospective-study-on-patients-with-bone-metastatic-cancer
#2
Derya Demirtas, Cemil Bilir, Abdullah Orhan Demirtas, Huseyin Engin
INTRODUCTION: There are controversial results in the risk of atrial fibrillation as well as arrhythmogenic potential of bis-phosphonates. METHOD: 37 patients and 40 healthy controls were evaluated prospectively with regard to the cardiac side effects related to the use of zoledronic acid (ZA) and its effects on electrocardiography (ECG) parameters. RESULT: As the basal ECG results of the patients diagnosed with cancer compared with the control group, it was determined that QT maximum was significantly lower, QT minimum was significantly higher...
January 2017: Clinical Cases in Mineral and Bone Metabolism
https://www.readbyqxmd.com/read/28737925/lipid-bilayer-gated-mesoporous-silica-nanocarriers-for-tumor-targeted-delivery-of-zoledronic-acid-in-vivo
#3
Diti Desai, Jixi Zhang, Jouko Sandholm, Jaakko Lehtimäki, Tove Grönroos, Johanna Tuomela, Jessica M Rosenholm
Zoledronic acid (ZOL) is a nitrogen-containing bisphosphonate used for the treatment of bone diseases and calcium metabolism. Anticancer activity of ZOL has been established, but its extraskeletal effects are limited due to its rapid uptake and accumulation to bone hydroxyapatite. In this work, we report on the development of tethered lipid bilayer-gated mesoporous silica nanocarriers (MSNs) for the incorporation, retention and intracellular delivery of ZOL. The in vitro anticancer activity of ZOL-loaded nanocarriers was evaluated by cell viability assay and live-cell imaging...
July 24, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28726113/glucocorticoid-sparing-effect-of-zoledronic-acid-in-sarcoid-hypercalcemia
#4
Mohammad Shafi Kuchay, Sunil Kumar Mishra, Beena Bansal, Khalid Jamal Farooqui, Lalitha Sekhar, Ambrish Mithal
INTRODUCTION: Glucocorticoids are regarded as first-line therapy in the management of hypercalcemia associated with sarcoidosis. However, prolonged glucocorticoid therapy leads to metabolic abnormalities, Cushingoid habitus, and impairment of bone health. This study demonstrates the efficacy and glucocorticoid-sparing effect of zoledronic acid in sarcoid hypercalcemia. METHODS: We present three patients with sarcoid hypercalcemia. They were successfully managed with oral glucocorticoids for many months...
December 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28721134/osteoporosis-in-men
#5
REVIEW
Waldemar Misiorowski
Osteoporotic fractures are the leading cause of morbidity and mortality among aging men. 30% of all hip fractures occur in men, and mortality resulting from not only the hip fracture, but also the spine and other major osteoporotic fractures, is significantly higher in men than in women. As in women, hypogonadism is the best documented risk factor for developing osteoporosis in men. In older men, testosterone levels are negatively correlated with the risk of fractures, and it seems that this age-related testosterone deficiency should not be considered as one of the many causes of secondary osteoporosis, rather one of the major and most important mechanisms of senile osteoporosis...
June 2017: Przeglad Menopauzalny, Menopause Review
https://www.readbyqxmd.com/read/28708644/comparison-of-the-effects-of-local-and-systemic-zoledronic-acid-application-on-mandibular-distraction-osteogenesis
#6
Serkan Dundar, Gokhan Artas, Izzet Acikan, Ferhan Yaman, Mustafa Kirtay, Muhammed Fatih Ozupek, Fatih Asutay, Mustafa Kom
Bisphosphonates are antibone resorptive drugs that are used to prevent bone tissue resorption in several skeletal diseases. The aim of this study was to examine the effects of systemic and local applications of zoledronic acid (ZA) on newly regenerated bone in a model of experimental distraction osteogenesis (DO). To do this mandibular DO was applied to 30 adult female Sprague Dawley rats, which were randomly divided into 3 groups: control, DO only, systemic zoledronic acid (SZA), and local zoledronic acid (LZA)...
July 13, 2017: Journal of Craniofacial Surgery
https://www.readbyqxmd.com/read/28703333/bone-tissue-response-following-local-drug-delivery-of-bisphosphonate-through-titanium-oxide-nanotube-implants-in-a-rabbit-model
#7
David H Kwon, Sang J Lee, Ulf M E Wikesjö, Petra Hammarström Johansson, Carina B Johansson, Young-Taeg Sul
OBJECTIVES: The objective of this study was to evaluate whether surface chemistry controlled TiO2 nanotube structures may serve as a local drug delivery system for zoledronic acid improving implant bone support. METHODS: Twenty-four screw-shaped Ti implants with surface chemistry controlled TiO2 nanotube structures were prepared and divided into a zoledronic acid-formatted test and a native control group. The implants were inserted into contralateral femoral condyles in 12 New Zealand White rabbits...
July 13, 2017: Journal of Clinical Periodontology
https://www.readbyqxmd.com/read/28695563/bone-targeted-therapies-in-advanced-breast-cancer
#8
Ewelina Biskup, Fengfeng Cai, Marcus Vetter
Bone targeted therapies are of increasing importance, not only for bone health in the clinical course of breast cancer, but recently also in the adjuvant setting as preventative, anticancer and prognosis-improving agents. It is well established that women with advanced breast cancer receive bisphosphonates or denosumab to prevent therapy-related osteoporosis. As many as 70% of these patients suffer from bone metastases and receive bone targeted agents in order to prevent skeletal related events (SREs), which are debilitating or diminish the quality of life...
July 11, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/28692257/targeting-osteocytes-to-attenuate-early-breast-cancer-bone-metastasis-by-theranostic-upconversion-nanoparticles-with-responsive-plumbagin-release
#9
Han Qiao, Zhaowen Cui, Shengbing Yang, Dingkun Ji, Yugang Wang, Ying Yang, Xiuguo Han, Qiming Fan, An Qin, Tingyu Wang, Xiao-Peng He, Wenbo Bu, Tingting Tang
The early detection and thus treatment of breast cancer bone metastasis remain a big challenge clinically. As the most abundant cells within bone tissue, osteocytes have been found to manipulate the activity of early cancer bone metastasis by its crosstalk with cancer cells and osteoclasts. However, conventional bone-targeting nanomedicine has limited bone-lesion specificity and ignores the vital role of osteocytes during breast cancer bone metastasis. Also, it lacks detailed insight into the therapeutic mechanisms, which hinders the following translational practice...
July 25, 2017: ACS Nano
https://www.readbyqxmd.com/read/28688625/bilateral-retrobulbar-optic-neuropathy-as-the-only-sign-of-zoledronic-acid-toxicity
#10
Félix Manco Lavado, Marta Para Prieto, María Rosalba Ramoa Osorio, María Isabel López Gálvez, Lucía Manzanas Leal
INTRODUCTION: Bisphosphonates may rarely cause ocular adverse effects and retrobulbar optic neuropathy (RON) secondary to zoledronic acid is very rare. CASE REPORT: A 67-year-old man was referred because of progressive and painless decrease vision in the left eye. He had been treated with 7 cycles of zoledronic acid infusions because of metastatic prostate cancer. On examination, VA was 20/20 in the right eye (OD) and 20/50 in the left eye (OS). The optic nerve was unremarkable OU...
July 5, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28688093/influence-of-bisphosphonates-on-the-adherence-and-metabolism-of-epithelial-cells-and-gingival-fibroblasts-to-titanium-surfaces
#11
Fernanda Gonçalves Basso, Taisa N Pansani, Diana G Soares, Lais M Cardoso, Josimeri Hebling, Carlos Alberto de Souza Costa
OBJECTIVES: To evaluate the effects of sodium alendronate (SA) and zoledronic acid (ZA), on the adhesion and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces considering cell functions related to an effective mucosal barrier around the implant. MATERIALS AND METHODS: Cells were seeded onto titanium discs and incubated for 24 h. Then, serum-free DMEM containing selected bisphosphonates (0, 0.5, 1, or 5 μM) was added for 24 and 48 h...
July 8, 2017: Clinical Oral Investigations
https://www.readbyqxmd.com/read/28685948/role-of-zoledronic-acid-in-oncolytic-virotherapy-promotion-of-antitumor-effect-and-prevention-of-bone-destruction
#12
Yasuaki Yamakawa, Hiroshi Tazawa, Joe Hasei, Shuhei Osaki, Toshinori Omori, Kazuhisa Sugiu, Tadashi Komatsubara, Kouji Uotani, Tomohiro Fujiwara, Aki Yoshida, Toshiyuki Kunisada, Yasuo Urata, Shunsuke Kagawa, Toshifumi Ozaki, Toshiyoshi Fujiwara
Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction. Although tumor-specific replicating oncolytic adenovirus OBP-301 induces an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruction. Zoledronic acid (ZOL) is a clinically available agent that inhibits bone destruction. In this study, we investigated the potential of combination therapy with OBP-301 and ZOL against osteosarcomas with bone destruction. The antitumor activity of OBP-301 and ZOL in monotherapy or combination therapy was assessed using 3 human osteosarcoma cell lines (143B, MNNG/HOS, SaOS-2)...
July 7, 2017: Cancer Science
https://www.readbyqxmd.com/read/28675810/use-of-leukocyte-and-platelet-rich-fibrin-in-the-treatment-of-medication-related-osteonecrosis-of-the-jaws
#13
Gustavo Maluf, Rogério Jardim Caldas, Paulo Sérgio Silva Santos
Lesions associated with medication-related osteonecrosis of the jaws (MRONJ) are refractory to different treatment approaches. Hence, auxiliary approaches capable of improving patient outcomes should be explored. Leukocyte- and platelet-rich fibrin (LPRF) is a second-generation platelet concentrate (natural autologous fibrin matrix). It shows anti-infectious activity through immune regulation and accelerates the angiogenesis and multiplication of fibroblasts and osteoblasts; in consequence, it stimulates soft tissue healing and prevents exposure of the alveolar bone in the oral cavity...
June 12, 2017: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/28666798/insights-into-the-mevalonate-pathway-in-the-anticancer-effect-of-a-platinum-complex-on-human-gastric-cancer-cells
#14
Ling Qiu, Hui Yang, Gaochao Lv, Ke Li, Guiqing Liu, Wei Wang, Shanshan Wang, Xueyu Zhao, Minhao Xie, Jianguo Lin
A platinum(II) complex [Pt(en)]2ZL [en = ethylenediamine; ZL = 1-hydroxy-3(1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid, commonly called as zoledronic acid] has been designed and synthesized recently in order to look for new anticancer drugs with high efficacy and low side effects. It exhibited cytotoxic effects on the human cancer cells SGC7901, HepG2, MCF-7, MDA-MB-231, HCT116, and U2OS, and the cytotoxicity against SGC7901 is particularly remarkable. It also showed higher cytotoxicity and better selectivity than the corresponding ligand ZL in inhibiting cancer cells SGC7901 and HepG2 rather than normal cells GES-1 and LO2...
June 27, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28655390/acute-granulomatous-interstitial-nephritis-and-acute-rejection-in-a-kidney-transplant-recipient-after-zoledronic-acid-therapy-a-case-report-and-review-of-the-literature
#15
Nuša Avguštin, Damjan Kovač, Nika Kojc, Gregor Mlinšek, Jelka Lindič
BACKGROUND: Acute granulomatous interstitial nephritis (AGIN) in native kidneys is most commonly linked to drugs. In allografts, it is a rare complication, and it occurs mostly with infections. CASE PRESENTATION: Our case report presents AGIN with simultaneous acute cellular rejections and acute tubular necrosis in a kidney transplant patient 2 weeks after intravenous application of zoledronic acid. A kidney biopsy showed signs of destructive AGIN with acute cellular rejection...
June 28, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28653350/zoledronic-acid-and-alendronate-sodium-and-the-implications-in-orthodontic-movement
#16
J S Franzoni, F M P Soares, E Zaniboni, M Vedovello Filho, M P Santamaria, G M T Dos Santos, M A M Esquisatto, M Felonato, F A S Mendonca, C M Franzini, M Santamaria
OBJECTIVE: To evaluate orthodontic tooth movement (OTM) in rats treated with two types of bisphosphonates (BPs), alendronate sodium (A) and zoledronic acid (Z). DESIGN: In all, 15 male Wistar rats were randomly divided into three groups. Group OTM+A: orthodontic tooth movement and subcutaneous administration of alendronate sodium (2.5 mg/kg); Group OTM+Z: orthodontic tooth movement and subcutaneous administration of zoledronic acid (0.02 mg/kg), and Group OTM: orthodontic tooth movement and subcutaneous injection of saline...
June 27, 2017: Orthodontics & Craniofacial Research
https://www.readbyqxmd.com/read/28652837/a-pilot-study-of-zoledronic-acid-in-the-treatment-of-patients-with-advanced-malignant-pleural-mesothelioma
#17
Muhammad Omer Jamil, Mary S Jerome, Deborah Miley, Katri S Selander, Francisco Robert
PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy with a dismal median survival of <12 months with current therapy. Single and combination chemotherapy regimens have shown only modest clinical benefit. In preclinical studies, nitrogen-containing bisphosphonates (zoledronic acid) inhibit growth of mesothelioma cells by different mechanisms: inhibition of mevalonate pathway, inhibition of angiogenesis, activation of apoptosis through caspase activation, and alteration in activity of matrix metalloproteinases, thereby affecting invasiveness of cancer cells...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28645291/the-effect-of-zoledronic-acid-on-type-and-volume-of-modic-changes-among-patients-with-low-back-pain
#18
Katri Koivisto, Jyri Järvinen, Jaro Karppinen, Marianne Haapea, Markus Paananen, Eero Kyllönen, Osmo Tervonen, Jaakko Niinimäki
BACKGROUND: Modic changes (MC) are associated with low back pain (LBP). In this study, we compared changes in size and type of MC, after a single intravenous infusion of 5 mg zoledronic acid (ZA) or placebo, among chronic LBP patients with MC on magnetic resonance imaging (MRI), and evaluated whether the MRI changes correlate with symptoms. METHODS: All patients (N = 19 in ZA, 20 in placebo) had MRI at baseline (0.23-1.5 T) and at one year (1.5-3 T). We evaluated the level, type and volume of all the MC...
June 23, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/28644302/the-role-of-bone-targeted-therapies-for-prostate-cancer-in-2017
#19
Samer L Traboulsi, Fred Saad
PURPOSE OF REVIEW: Bone-targeted agents (BTAs), such as zoledronic acid and denosumab, delay the occurrence of skeletal-related events (SREs) in metastatic prostate cancer (PCa) patients. Recently, several agents, such as abiraterone acetate, enzalutamide and radium-223, were approved for the treatment of metastatic castration-resistant PCa (mCRPC). These agents resulted in improved overall survival (OS), pain control and had positive effects on bone health. Combining BTAs to the newly approved agents demonstrates additional benefits that warrant a review of available evidence looking at appropriate combination therapies and timing of BTAs for optimizing the management of advanced and metastatic PCa...
July 20, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28643933/oncologic-doses-of-zoledronic-acid-induce-site-specific-suppression-of-bone-modelling-in-rice-rats
#20
C R Exposto, U Oz, J S Callard, M J Allen, H Khurana, A D' Atri, X Mo, S A Fernandez, D N Tatakis, K Edmonds, P M Westgate, S S Huja
OBJECTIVES: To examine the effect of zoledronic acid (ZOL) on cortical bone modelling and healing of extraction sockets in the jaw bones of a rodent model. We hypothesized ZOL suppresses both the bone formation in the modelling mode in the jaw bones and alters the extraction site healing. MATERIAL & METHODS: Rice rats were administered saline solution and two dose regimens of ZOL: 0.1 mg/kg, twice a week, for 4 weeks (n=17, saline=8 & ZOL=9) and a higher dose of 0...
June 2017: Orthodontics & Craniofacial Research
keyword
keyword
27337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"